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Abstract
Introduction: We present the case of a 49-year-old woman with a seronegative rheumatoid
arthritis who developed pustular psoriasis whilst on etanercept and subsequently developed
disseminated herpes simplex on infliximab.
Case presentation: Our patient presented with an inflammatory arthritis which failed to respond
to both methotrexate and leflunomide, and sulphasalazine treatment led to side effects. She was
started on etanercept but after 8 months of treatment developed scaly pustular lesions on her
palms and soles typical of pustular psoriasis. Following the discontinuation of etanercept, our
patient required high doses of oral prednisolone to control her inflammatory arthritis. A second
biologic agent, infliximab, was introduced in addition to low-dose methotrexate and 15 mg of oral
prednisolone. However, after just 3 infusions of infliximab, she was admitted to hospital with a
fever, widespread itchy vesicular rash and worsening inflammatory arthritis. Fluid from skin vesicles
examined by polymerase chain reaction showed Herpes Simplex Virus type 1. Blood cultures were
negative and her chest X-ray was normal. Her infliximab was discontinued and she was started on
acyclovir, 800 mg five times daily for 2 weeks. She made a good recovery with improvement in her
skin within 48 hours.
She continued for 2 months on a prophylactic dose of 400 mg bd. Her rheumatoid arthritis became
increasingly active and a decision was made to introduce adalimumab alongside acyclovir. Acyclovir
prophylaxis has been continued but the dose tapered so that she is taking only 200 mg of acyclovir
on alternate days. There has been no recurrence of Herpes Simplex Virus lesions despite increasing
adalimumab to 40 mg weekly 3 months after starting treatment.
Conclusion: We believe this to be the first reported case of widespread cutaneous Herpes
Simplex Virus type 1 infection following treatment with infliximab. We discuss the clinical
manifestations of Herpes Simplex Virus infections with particular emphasis on the
immunosuppressed patient and the use of prophylactic acyclovir. Pustular psoriasis is now a well
recognised but uncommon side effect of antitumour necrosis factor therapy and can lead to
cessation of therapy, as in our patient's case.
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Introduction and Case presentation
We describe a 49-year-old woman with seronegative pol-
yarthritis who developed pustular psoriasis whilst on
etanercept and subsequently developed disseminated her-
pes simplex on infliximab in combination with meth-
otrexate. Our patient presented in 2004 and was initially
treated with methotrexate. She was unable to tolerate
doses beyond 15 mg per week because of troublesome
mouth ulcers. Her disease failed to come under control
and she was dependent on oral prednisolone at doses
above 20 mg. After 5 months, she was switched to sul-
phasalazine 3 g daily. She developed severe headaches
and 3 months later was switched to leflunomide 20 mg
daily without any clinical improvement. Her erythrocyte
sedimentation rate (ESR) was raised at 44 mm/hour
despite oral prednisolone at 25 mg daily and 10 months
after diagnosis was started on Etanercept 25 mg subcuta-
neous injections twice weekly combined with low-dose
oral methotrexate (10 mg/week). Three months later, her
ESR had fallen to 26 mm/hour and the oral prednisolone
reduced to 10 mg daily. Eight months after starting etaner-
cept, she developed scaly pustular lesions on her palms
and soles typical of pustular psoriasis (Fig. 1). She ceased
etanercept temporarily and her skin improved markedly
but her arthritis worsened. On restarting etanercept, the
pustular psoriasis recurred. She switched to infliximab,
administered intravenously at a dose of 3 mg/kg, and she
received the first 3 infusions over the course of 6 weeks.
Three weeks after her third infusion, she was admitted to
hospital with a fever, a widespread vesicular rash (Fig. 2)
and a flare of her arthritis. On admission, she was taking
prednisolone 15 mg daily and methotrexate 5 mg weekly.
Her full blood count revealed a total count of 17.5 × 109
with a neutrophilia of 10.9 × 109, a C-reactive protein of
153 mg/litre, and an ESR of 75 mm/hour. Renal and liver
function tests were normal and immunoglobulins A, G
and M were normal. There was no growth on blood cul-
tures and her chest X-ray (CXR) was unremarkable. Fluid
from skin vesicles examined by polymerase chain reaction
showed Herpes Simplex Virus type 1 (HSV-1). Serological
tests showed no evidence of acute Varicella Zoster Virus
but indicated past exposure. Infliximab was discontinued
and acyclovir 800 mg five times daily was given for 2
weeks. She improved systemically and her vesicular rash
started to resolve within 48 hours of acyclovir.
The dose of acyclovir was then reduced to 400 mg twice
daily and after 2 months on this dose, she commenced a
third anti-TNF agent adalimumab, 40 mg subcutaneous
injections once a fortnight. Acyclovir prophylaxis has
been continued, so far, for 8 months but the dose tapered
so that she is taking only 200 mg of acyclovir on alternate
days. There has been no recurrence of HSV-1 lesions
despite increasing adalimumab to 40 mg weekly 3
months after starting treatment. Her current dose of pred-
nisolone is 10 mg od.
Discussion
We believe that this is the first description of widespread
cutaneous HSV-1 infection following treatment with inf-
liximab. Our patient also developed pustular psoriasis
whilst taking etanercept and the psoriasis worsened on re-
challenge with etanercept.
HSV-1 is one of the ubiquitous herpes family of viruses
usually transmitted during childhood. Around 60% of
adults show evidence of past infection and the primary
infection is often mild or asymptomatic [1]. Reactivation
of the virus following latency in the sensory ganglia can
happen years later and manifest usually as cold sores.
Characteristically painful vesicles develop in a localised
area such as the lip which subsequently progress over days
Scaly pustular lesions on soles of feet typical of pustular pso- riasis Figure 1
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to non-scarring scabs. The extent of cutaneous disease is
determined by a number of host factors including age,
intercurrent illness, immune status and presence of pre-
existing skin disease. Disseminated cutaneous disease
may occur in immunocompromised patients, especially
those with haematological malignancies and following
bone marrow and organ transplants. Encephalitis [2],
hepatitis [3] and pneumonia [4] caused by HSV are also
more common in immunocompromised patients.
We are not aware of any published reports of serious HSV
infections associated with use of TNF inhibitors and can-
not say whether treatment with infliximab, steroids alone,
or the drug combination caused disseminated HSV-1 in
our patient. In vivo data indicate that TNF-alpha may have
an antiviral effect in HSV-1 infections. In a model in
which HSV-1 was reactivated in latently infected mice cor-
nea, TNF-α and interleukin-6 were the predominant
cytokines within the trigeminal ganglion suggesting a key
role for these cytokines in viral clearance [5]. Absence of
TNF in knockout mice increased susceptibility to primary
corneal HSV-1 infections in one study [6] and lowered
survival rates compared with wild-type mice in another
(83% cf 97%) [7]. Whilst all three TNF inhibitors used in
clinical practice inhibit the actions of TNF-α, their differ-
ent mechanisms of action may result in a variable suscep-
tibility to HSV-1 infections, although this has not
specifically been studied.
In vitro studies of gingival fibroblasts showed that cells
pretreated with dexamethasone and infected with HSV-1
gave rise to higher yields of virus [8] suggesting that corti-
costeroids increase susceptibility to infection in these
cells. Recipients of renal transplants on high doses of
prednisolone (above 25 mg daily) are reported to have
twice the rate of HSV infections compared with those on
lower doses including primary infections in seronegative
patients and re-infections of seropositive patients [9].
Unfortunately, this study does not report the severity and
nature of HSV-1 infections seen.
In several small placebo-controlled trials, prophylactic use
of oral acyclovir in immunocompromised patients has
been found to be successful in reducing the duration of
viral shedding and preventing clinical HSV infections in
80% to 100% of patients [10]. The oral doses studied were
200 mg tds for 30 days and 200 mg qds for 180 days. In
both studies, there were no additional adverse events
compared with placebo. The most frequently reported
adverse effects during acyclovir therapy are headache,
nausea and abdominal cramping. Whilst oral acyclovir
has a good safety profile, cases of rapidly progressive acute
neurological and renal toxicity have been described [11].
Acyclovir-induced neurotoxicity can present with a variety
of symptoms including agitation, delirium and hallucina-
tions [12]. Dose reductions are recommended in patients
with renal impairment and in the elderly. Our patient
received 400 mg twice a day for 4 months and has since
reduced the dose to 200 mg alternate daily. Whilst current
evidence around the optimum duration and dose for
long-term prophylaxis is lacking, a decision to continue
on this low level of therapy was taken with the patient
because of concerns about infection recurrence. Once acy-
clovir therapy is discontinued, there is no ongoing protec-
tion against HSV infections.
Pustular psoriasis and psoriasis are an uncommon but rec-
ognized adverse event associated with TNF-α inhibition.
The British Society for Rheumatology Biologics Register
reported that, among 8672 patients with rheumatoid
arthritis treated with anti-TNF therapy, there were 23
reports of a new onset of psoriasis in patients with no pre-
vious history of psoriasis and one patient with a family
history of psoriasis. Eight of the 23 patients stopped treat-
ment and of those, six reported an improvement in their
psoriasis. Overall psoriasis rates were over four times
higher in patients treated with TNF-α inhibitors compared
with patients treated with other disease modifying
antirheumatic drugs [13]. One large case series of 13
patients included only one case induced specifically by
etanercept [14].
There is no clear explanation as to the nature of this phe-
nomenon. Sfikakis et al. postulate that under certain con-
ditions, TNF-α inhibition promotes the activation of
autoreactive T cells leading to tissue damage via autoim-
mune pathways [15] whilst De Gannes et al. speculate that
increased expression of interferon-α in the dermal vascu-
lature may increase susceptibility to psoriatic skin lesions
[14].
Conclusion
This is the first reported case of disseminated cutaneous
HSV-1 infection following treatment with infliximab in a
Vesicular rash on lower legs Figure 2
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patient with rheumatoid arthritis. We believe this unusual
adverse reaction to be as a direct result of her immunosup-
pressive therapy.
Prophylactic acyclovir may reduce the frequency and
severity of recurrent HSV attacks although the exact dose
and duration of therapy are uncertain and likely to vary
according to individual circumstances.
Our patient had also developed pustular psoriasis whilst
on etanercept. Psoriatic skin reactions are a recognised but
uncommon side effect of anti-TNF therapy and may
require cessation of treatment.
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